Genmab A/S (GNMSF) News Today $224.30 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock GNMSF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Genmab Advances Share Buy-back Program in June 2025June 10, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Above Fifty Day Moving Average - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?June 6, 2025 | marketbeat.comASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive dataJune 4, 2025 | msn.comGenmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial CancerJune 3, 2025 | insidermonkey.comGenmab A/S (OTCMKTS:GNMSF) Short Interest UpdateGenmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a large increase in short interest in May. As of May 15th, there was short interest totalling 146,300 shares, an increase of 98.0% from the April 30th total of 73,900 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 3,400 shares, the days-to-cover ratio is currently 43.0 days.June 1, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50-Day Moving Average - Here's What HappenedGenmab A/S (OTCMKTS:GNMSF) Shares Pass Above Fifty Day Moving Average - Here's What HappenedMay 30, 2025 | marketbeat.comGenmab Executes Share Buy-back Transactions in May 2025May 27, 2025 | tipranks.comGenmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025May 24, 2025 | finance.yahoo.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above 50-Day Moving Average - Here's WhyGenmab A/S (OTCMKTS:GNMSF) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?May 23, 2025 | marketbeat.comGenmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025May 23, 2025 | insidermonkey.comGenmab announces share buy-back transactionsMay 21, 2025 | investing.comGenmab A/S Updates Articles to Enhance Capital FlexibilityMay 21, 2025 | tipranks.comGenmab Executes Share Buy-back Transactions in May 2025May 19, 2025 | tipranks.comGenmab A/S: Transitioning From Royalty Model To Commercial-Stage OncologyMay 19, 2025 | seekingalpha.comGenmab Executes Share Buy-back Transactions in May 2025May 12, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Posts Earnings Results, Beats Expectations By $1.17 EPSGenmab A/S (OTCMKTS:GNMSF - Get Free Report) issued its earnings results on Thursday. The company reported $3.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.88 by $1.17. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%. The business had revenue of $765.14 million during the quarter, compared to analyst estimates of $761.09 million.May 12, 2025 | marketbeat.comGenmab A/S: Genmab Announces Financial Results for the First Quarter of 2024May 10, 2025 | finanznachrichten.deGenmab Executes Share Buy-back Transactions in Early May 2025May 5, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Short Interest Up 30.1% in AprilGenmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 73,000 shares, an increase of 30.1% from the March 31st total of 56,100 shares. Currently, 0.1% of the company's shares are sold short. Based on an average daily volume of 16,800 shares, the short-interest ratio is presently 4.3 days.May 4, 2025 | marketbeat.comIs Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?May 1, 2025 | insidermonkey.comGenmab Continues Share Buy-back Program in April 2025April 28, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average - What's Next?Genmab A/S (OTCMKTS:GNMSF) Shares Cross Below 200-Day Moving Average - Time to Sell?April 26, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below 200 Day Moving Average - Here's WhyGenmab A/S (OTCMKTS:GNMSF) Share Price Crosses Below Two Hundred Day Moving Average - Here's WhyApril 17, 2025 | marketbeat.comGenmab Advances Share Buy-back Program with Significant TransactionsApril 14, 2025 | tipranks.comGenmab A/S Updates Articles of Association to Enhance Capital FlexibilityApril 10, 2025 | tipranks.comGenmab A/S Share Capital ReductionApril 10, 2025 | investing.comGenmab A/S (OTCMKTS:GNMSF) Hits New 12-Month Low - Here's What HappenedGenmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year Low - Should You Sell?April 10, 2025 | marketbeat.comGenmab A/S Advances Share Buy-back Program as of April 2025April 7, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Hits New 1-Year Low - Here's WhyGenmab A/S (OTCMKTS:GNMSF) Sets New 1-Year Low - What's Next?April 4, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average - What's Next?Genmab A/S (OTCMKTS:GNMSF) Shares Cross Below 200 Day Moving Average - Time to Sell?April 3, 2025 | marketbeat.comIs Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?April 2, 2025 | insidermonkey.comGenmab Discloses Managerial Share TransactionsApril 1, 2025 | tipranks.comGenmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent ConcernsApril 1, 2025 | tipranks.comGenmab’s Tivdak approved in Japan for advanced cervical cancerMarch 28, 2025 | msn.comGenmab A/S Updates Articles of Association to Enhance Financial FlexibilityMarch 20, 2025 | tipranks.comGenmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trialMarch 17, 2025 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Share Price Crosses Below 200 Day Moving Average - Should You Sell?March 13, 2025 | marketbeat.comGenmab price target lowered to DKK 2,300 from DKK 2,400 at RBC CapitalMarch 12, 2025 | markets.businessinsider.comGenmab A/S (0MGB) Gets a Buy from BarclaysMarch 12, 2025 | markets.businessinsider.comGenmab A/S Announces Board Constitution and Stock GrantsMarch 12, 2025 | tipranks.comGenmab A/S Approves 2024 Annual Report and Strategic Proposals at AGMMarch 12, 2025 | tipranks.comIs Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?March 8, 2025 | insidermonkey.comGenmab A/S Discloses Executive Share TransactionsMarch 4, 2025 | tipranks.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 4, 2025 | investing.comGenmab A/S Updates Articles of Association to Enhance Financial FlexibilityFebruary 26, 2025 | tipranks.comGenmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to AnalystsFebruary 25, 2025 | insidermonkey.comGenmab A/S Announces Capital Increase Following Employee Warrant ExerciseFebruary 25, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Above 50-Day Moving Average - What's Next?Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Above 50-Day Moving Average - Here's What HappenedFebruary 25, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short InterestGenmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a decrease of 20.5% from the January 15th total of 101,800 shares. Based on an average daily volume of 21,300 shares, the days-to-cover ratio is presently 3.8 days.February 16, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Estimates By $5.24 EPSGenmab A/S (OTCMKTS:GNMSF - Get Free Report) announced its earnings results on Wednesday. The company reported $5.70 earnings per share for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 23.49% and a return on equity of 17.73%.February 15, 2025 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Media Mentions By Week GNMSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼1.110.89▲Average Medical News Sentiment GNMSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼12▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today Daiichi Sankyo News Today argenx News Today Beigene News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
